Featured Resources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
About us
Working With Us
Whether we’re supporting you through the entire drug discovery process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
Our Team
More than 70% of Sygnature’s scientists hold a PhD, and many bring extensive pharmaceutical industry experience to every project we undertake. This expertise enables us to collaborate as true scientific partners with our customers, providing meaningful intellectual input and drug discovery know-how to help advance their programs towards the clinic. We act as an extension of your team.
Our approach is built on forming genuine partnerships. That means maintaining clear, open communication at every stage, offering honest insights into project viability, and recommending the best path forward.
What makes us different?
Focused expertise
Complex challenges need total commitment. With no competing internal programs, our world-class scientists are driven by your priorities alone. From targeted expertise to integrated partnerships, you always get our best people and dedicated support.
Scientific integrity
Cutting-edge research depends on transparency. Our track record is built on honesty, quality over quantity, and the most rigorous data standards. You can trust us to challenge constructively and communicate quickly, whether the news is good or challenging.
Scientific momentum
Every breakthrough starts with a spirit of curiosity. Together, we’ll innovate through advanced technologies and experimentation, exploring new pathways to your destination. So you can accelerate from insight to outcome, without sacrificing excellence.
Borderless resources
Removing barriers drives better outcomes. Our labs across Europe and North America offer unmatched scale and breadth, bringing together different disciplines in shared spaces. Tap into expertise across sites, when and where you need it: global capabilities, delivered locally.
Our Track Record
Since 2011, we’ve advanced more than 60 candidates across a range of key therapeutic areas, from immunology and oncology to neuroscience and infectious disease, including 23 preclinical and 36 clinical assets, with 2 approved. This breadth demonstrates our ability to drive complex, high-value discovery programs into the clinic and to lay the foundations for a meaningful impact on patients.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Sitryx: Empowering New Ideas
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Corcept Therapeutics: Integrated Drug Discovery Collaboration
Corcept Therapeutics, located in Menlo Park, CA, is a leader in the discovery and development of drugs that regulate the effects of cortisol.
CellCentric Lead Optimisation Campaign – CCS1477
CellCentric are developing new treatments for cancer based on their understanding of epigenetics.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates
UK-based small molecule drug discovery company
Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD
